These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34231370)

  • 1. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application.
    Xiao G; Liu Z; Gao X; Wang H; Peng H; Li J; Yang L; Duan H; Zhou R
    Immunotherapy; 2021 Aug; 13(12):1031-1051. PubMed ID: 34231370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
    Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
    Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.
    Nunno VD; Nuvola G; Mosca M; Maggio I; Gatto L; Tosoni A; Lodi R; Franceschi E; Brandes AA
    Immunotherapy; 2021 Apr; 13(5):419-432. PubMed ID: 33472433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases.
    Wu X; Stabile LP; Burns TF
    Clin Lung Cancer; 2024 Sep; 25(6):483-501. PubMed ID: 38991863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
    Front Immunol; 2021; 12():697298. PubMed ID: 34858389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain Metastases.
    Mahashabde R; Bhatti SA; Martin BC; Painter JT; Rodriguez A; Ying J; Li C
    JCO Oncol Pract; 2023 Nov; 19(11):1009-1019. PubMed ID: 37729600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases.
    Wei Y; Xu Y; Wang M
    Chin Med J (Engl); 2023 Jul; 136(13):1523-1531. PubMed ID: 37106555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
    La-Beck NM; Nguyen DT; Le AD; Alzghari SK; Trinh ST
    Pharmacotherapy; 2020 Mar; 40(3):239-255. PubMed ID: 31930528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC.
    Rijavec E; Indini A; Ghidini M; Tomasello G; Cattaneo M; Barbin F; Grossi F
    Expert Rev Anticancer Ther; 2021 Jul; 21(7):705-713. PubMed ID: 33719827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.
    Metro G; Gili A; Signorelli D; De Toma A; Garaffa M; Galetta D; Economopoulou P; Friedlaender A; Jimenez B; Collazo-Lorduy A; Addeo A; Chiarini P; Costa C; Mountzios G; Roila F
    Clin Transl Oncol; 2021 Sep; 23(9):1818-1826. PubMed ID: 33728869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
    BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1 
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis].
    Sheng J; Yu X; Li H; Fan Y
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):976-982. PubMed ID: 32773010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
    Uruga H; Mino-Kenudson M
    Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y; Luo H; Zheng XL; Ge H
    Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatment.
    Glode AE; May MB
    Am J Health Syst Pharm; 2021 Apr; 78(9):769-780. PubMed ID: 33580648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.